Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Eyenovia Inc
EYEN | US
0.56
USD-0.02
-2.94%
EYEN | US
About Eyenovia Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.56
Open
0.58
High
0.58
Low
0.53
Eyenovia Inc. a pre-commercial ophthalmic company engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine MicroLine and Mydcombi in China and South Korea; and Senju Pharmaceutical Co. Ltd. to develop and commercialize MicroPine MicroLine and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V Inc. and changed its name to Eyenovia Inc. in May 2014. Eyenovia Inc. was incorporated in 2014 and is headquartered in New York New York.
View LessEYEN | US
Risk
110.0
Sharpe
-0.53
Luna's Score
42/100
Recommendation
Sell
Luna says (EYEN | US)
What's Working
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
134.9%1 month
110.0%3 months
127.0%6 months
134.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
36.17
Debt to equity
-6.62
Debt to assets
0.83
Ent. to EBITDA
-5.41
Ent. to rev.
1.98K
PEG
-
Other Fundamentals
EBITDA
-34.80M
MarketCap
47.51M
MarketCap(USD)
47.51M
Div. yield
-
Op. margin
-51.66K
Erngs. growth
-
Rev. growth
400.00
Ret. on equity
-914.66
Short ratio
2.69
Short perc.
4.13
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.16
Range1M
0.16
Range3M
1.19
Volumes: Market Activity
Rel. volume
1.00
Price X volume
512.37K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.41 | 0.53 | Cheaper |
| Ent. to Revenue | 1,984.08 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 36.17 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 127.00 | 72.80 | Riskier |
| Debt to Equity | -6.62 | -1.23 | Cheaper |
| Debt to Assets | 0.83 | 0.25 | Expensive |
| Market Cap | 47.51M | 3.66B | Emerging |
